Olema Pharmaceuticals (OLMA) - Due Diligence

hourglass

Caricamento company...

Sto preparando dati, stili e contenuti aggiornati della DD.

62OpportunityDD: Jun 25, 2026Analyst: 58

paidPrice

$9.51

domainMkt cap

$830M

pie_chartShares

candlestick_chart52W

$3.89-$36.26

trending_downShort interest

10%

MEDIUMNASDAQClinical-stage Oncology (Breast Cancer)137 employeesFounded 2014

Verdict: Favorable Risk/Reward —

Binary biotech with a cash floor covering ~55–60% of market cap, a dated Phase 3 catalyst (OPERA-01 topline, fall 2026) and dual validation from Novartis (OPERA-02 CTSA + $250M PIPE) and Bayer (OP-3136 CTSA in mCRPC). Asymmetric setup: base FV ~$17, bull ~$30+, bear ~$5; downside to floor anchored at cash/share. Class-level setbacks (Sanofi amcenestrant, G1 rintodestrant) keep PoS realistically at 30–40%, not the 50–60% implied by sell-side $42 mean PT.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-25

Olema Pharmaceuticals (OLMA)

Clinical-stage Biotech (Oncology — Breast Cancer SERD) · NASDAQ · San Francisco

"Net-cash anchored binary; favorable asymmetry if you can stomach Phase 3 OPERA-01."

Cash > 55% MC Phase 3 readout Q4'26 Novartis + Bayer CTSA Binary outcome Class PoS ~30–40%

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV (probability-weighted, sum-of-parts)

Fair value base case

USD 17.0

Range: USD 13.0-USD 22.0

Current price ~USD 9.51

Base upside/downside: +79%

Methodology: Probability-weighted rNPV (0.20 × $37 + 0.45 × $17 + 0.35 × $5.50 = $7.40 + $7.65 + $1.93 = $16.98 blended , consistent with the additive base case at $17.08). Implicit pipeline EV multiple of 1.06x risk-adjusted peak sales is appropriate for a Phase 3 SERD with mixed class read-throughs. Bull-coda weight 20% (NOT 35–40%) reflects honest PoS calibration on next-gen SERDs (~30–40% historical class success), not bullish anchoring. The asymmetry vs current price (+79% to base, +250% to bull, −47% to bear ⇒ ratio ~3.0x) survives the gate strictly. ⚠️ Not investment advice.

Component	Assumption	USD/share
Palazestrant monotherapy (OPERA-01, 2/3L mBC)	$1.2B peak WW sales × 3.5x EV/peak × 30% PoS = $1.26B risk-adj / 100.9M FD shares	+12.50
Palazestrant + ribociclib (OPERA-02, 1L)	$0.7B peak × 3.0x × 20% PoS = $420M risk-adj / 100.9M (Novartis CTSA partial validation)	+4.16
OP-3136 KAT6 option (Phase 1, mCRPC + mBC)	25% prob × $400M platform NPV / 100.9M (Bayer CTSA datapoint)	+0.99
Net cash floor (Q2'26E adj.)	$505M cash Q1'26 − ~$55M Q2 burn + future PIPE proceeds ≈ $450M / 100.9M FD	+4.46
G&A + R&A burn discount (to next catalyst)	~2 years × $210M burn × 50% (partially offset by collab milestones) = −$210M / 100.9M	−2.08
Dilution reserve (next 12-18m raise)	10% expected dilution at $10/sh average pricing reflected via per-share denominator drag	−2.95
FV base case	Sum of rows above (12.50 + 4.16 + 0.99 + 4.46 − 2.08 − 2.95)	≈ $17.08

Bull

$32–42

Probability: 20%

OPERA-01 hits PFS and ORR endpoints, ESR1-mut subgroup statistically significant, label opens 2/3L mBC. Re-rating to peer median multiple of late-stage de-risked SERD; M&A optionality (AZN, AbbVie, Lilly) caps the upside.

Base

$13–22

Probability: 45%

OPERA-01 mixed (sub-group win, ITT marginal) à la imlunestrant: regulatory pathway exists but narrow label; OPERA-02 still pending; risk-adjusted rNPV anchored at ~$17 with continued PoS uncertainty on combo readout.

Bear

$4–7

Probability: 35%

OPERA-01 misses primary, joining amcenestrant/rintodestrant in the failed-SERD bin. Stock collapses to ~70–80% of cash/share ($3.50–$4.00) with residual OP-3136 option (~$1/sh). PIPE investors underwater, dilution risk rises.

Methodology: Methodology: Probability-weighted rNPV (0.20 × $37 + 0.45 × $17 + 0.35 × $5.50 = $7.40 + $7.65 + $1.93 = $16.98 blended , consistent with the additive base case at $17.08). Implicit pipeline EV multiple of 1.06x risk-adjusted peak sales is appropriate for a Phase 3 SERD with mixed class read-throughs. Bull-coda weight 20% (NOT 35–40%) reflects honest PoS calibration on next-gen SERDs (~30–40% historical class success), not bullish anchoring. The asymmetry vs current price (+79% to base, +250% to bull, −47% to bear ⇒ ratio ~3.0x) survives the gate strictly. ⚠️ Not investment advice. Not investment advice.

⚠️ Methodology note: OLMA is a pre-revenue clinical-stage biotech: valuation is built bottom-up via risk-adjusted NPV (rNPV) per program (palazestrant monotherapy, palazestrant + ribociclib combo, OP-3136 KAT6 option) plus net cash floor. Standard P/E or EV/EBITDA multiples do not apply. Peer table uses Phase 3 oncology smid-caps for cash-to-MC and EV-to-program-value relative checks.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~9–11%

~8–10M shares short on 87.3M common float. Moderate; consistent with binary biotech setup ahead of Phase 3 readout. Squeeze potential limited.

🔴 Share dilution (1Y)

+45%

From ~60M shares end-2024 to 87.3M common + 13.6M pre-funded warrants (100.9M FD) end-Q1'26. Driver: Nov 2025 follow-on $218M + Mar 2026 Novartis-linked PIPE $250M.

🔴 Buyback

No buyback program (pre-revenue biotech). Capital priority is funding OPERA-01 + OPERA-02 readouts and OP-3136 dose-escalation. Reasonable for the stage.

Short Interest — context

OLMA — ~10%

~10%

SI in the 9–11% range is typical for clinical-stage biotechs entering a binary readout window. It signals hedging by long-only holders and event-driven short positioning rather than a fundamental short thesis. Pre-funded warrants (13.6M) are an additional overhang that becomes shares on PoS trigger and should be modeled into the FD count, as done in the FV table.

$Financial analysis — FY 2025 + Q1 2026

Cash & equivalents (Q1'26)

$505.3M

+$93M vs Q4'25 (PIPE inflow)

Net loss (Q1'26)

$53.1M

EPS −$0.52

Annualized burn rate

~$210M

Cash runway ~2.4 years

Net debt

Debt-free balance sheet

Item	FY2023	FY2024	FY2025	FY2026E	Guidance 2027
Revenue ($M)	0	0	0	0	0 (pre-launch)
R&D expense ($M)	82	128	158	~175	~190
G&A expense ($M)	28	34	42	~48	~52
Net loss ($M)	−96	−149	−185	~−210	~−225
Cash & equivalents ($M)	331	295	505	~450	~285 (pre-raise)
Shares outstanding FD (M)	49	60	87	101	~110 (assumed raise)

Note: FY2026E guidance not formally disclosed by management; figures are estimates extrapolated from Q1'26 actuals and stated trial-cost ramp. Revenue remains nil until palazestrant approval/launch (earliest 2H 2027 if OPERA-01 hits).

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	0.0	0.0	0.0	0.0	0.0
R&D expense ($M)	32.5	37.2	41.8	46.5	44.1
Net loss ($M)	−36.4	−42.1	−47.8	−58.7	−53.1
End-of-period cash ($M)	277	237	419	412	505

Financial position and sustainability

Cash runway to next catalyst

~2.4 years

Cash as % of market cap

~61%

Net-cash anchored downside (vs price)

~47%

account_tree

Business model — Three-program oncology pipeline

Olema in one slide

San Francisco-based clinical-stage biotech focused on endocrine-driven women's cancers. Lead asset palazestrant (OP-1250) is a complete estrogen receptor antagonist + degrader (CERAN/SERD) in Phase 3 for ER+/HER2- metastatic breast cancer (mBC), targeting the post-progression segment (~$5–7B WW annual market) currently anchored by Lilly's elacestrant. Second program OP-3136 is a first-in-class oral KAT6/KAT7 inhibitor in Phase 1, expanding into prostate cancer via Bayer partnership. The bet: best-in-class oral SERD with superior tolerability and durability vs class peers (camizestrant approved, imlunestrant mixed, amcenestrant/rintodestrant failed).

Palazestrant monotherapy (OPERA-01) ~$1.2B peak WW · 30% PoS 🟡 readout fall 2026 Phase 3 2L/3L ER+/HER2- mBC, ITT + ESR1-mut co-primary. Direct comp to elacestrant; differentiation = full antagonism + degradation, oral once-daily. Single biggest value driver and primary binary catalyst. Palazestrant + ribociclib (OPERA-02) ~$0.7B peak · 20% PoS 🟢 enrolling Phase 3 1L mBC combination. Novartis supplies ribociclib (Kisqali) under CTSA; $250M concurrent PIPE provides commercial signal. Readout 2028. Larger TAM (1L) but higher bar vs current SOC. OP-3136 (KAT6/KAT7 inhibitor) Option · 25% prob × $400M 🟢 Phase 1 First-in-class oral epigenetic inhibitor; ASCO 2026 data showed early efficacy + favorable tolerability. Bayer CTSA in mCRPC (with darolutamide) initiates H2'26. Pure optionality, not in base case.

gavel

Legal, regulatory and risk analysis

OPERA-01 binary readout (PFS endpoint)

Critical

Fall 2026 topline data. Next-gen SERD class has ~40% Phase 3 success rate historically (AZN ✓, Lilly partial, Sanofi ✗, G1 ✗). A miss takes the stock to ~$4–5; a hit re-rates to $30+. Single largest determinant of investment outcome.

Cash burn vs runway

Low

$505M cash Q1'26 vs ~$210M annualized burn = ~2.4 years runway, comfortably past OPERA-01 readout and well into OPERA-02 enrollment. Best-in-class for stage among Phase 3 oncology smid-caps.

Securities class action / governance

Moderate

DJS Law Group announced investigation March 2026 around stock decline (no formal complaint yet to our knowledge). Standard biotech "stock drop" template; not value-affecting unless escalates to class certification with quantifiable damages.

Dilution overhang (pre-funded warrants)

Moderate

13.6M pre-funded warrants (~14% additional dilution potential) plus high likelihood of a $200–300M raise post-readout regardless of outcome. Modeled into FD share count (100.9M) and dilution reserve line of the FV table.

Novartis & Bayer validation

Positive

Two top-10 pharmas committed to combination studies (ribociclib for OPERA-02; darolutamide for OP-3136). External diligence from sophisticated counterparties materially de-risks the chemistry/MoA story; not a guarantee of OPERA-01 success.

Net cash floor / downside protection

Positive

$5/sh net cash vs $9.50 stock price = ~47% maximum downside even in OPERA-01 failure (typical biotech post-failure floor is 60–80% of cash/share). Asymmetric setup is mathematically real.

Commercial execution risk (if approved)

High

No commercial infrastructure; either build (~$200M, 2–3 years) or partner. Elacestrant (Stemline/Menarini) launched slowly. Olema would face uphill battle against entrenched SOC + AZN camizestrant launched 2026.

Sell-side over-anchoring

Moderate

Mean PT $42 with Citi at $62 and JPM at $58 embed implicit PoS of 50–60% on palazestrant. Goldman ($27) and Wolfe ("Peer Perform") more cautious. Our 30% PoS is closer to bears; if street is right, base FV is ~$25 not $17.

article

SWOT analysis

Strengths

+Cash position of $505M (~61% of market cap) provides genuine downside anchor
+Phase 3 OPERA-01 fully enrolled with dated readout (Q4 2026) — concrete catalyst
+Novartis (OPERA-02 + $250M PIPE) and Bayer (OP-3136 mCRPC) CTSAs = external validation
+Debt-free balance sheet; ~2.4 years runway past primary catalyst
+CERAN mechanism differentiates vs competing SERDs both on potency and tolerability profile

Weaknesses

−Pre-revenue: $185M FY25 net loss, no commercial infrastructure
−+45% dilution YoY from two financings; another raise likely post-readout regardless of outcome
−Single-asset concentration: OPERA-01 success/failure drives 80%+ of equity value
−Class track record mixed: 2 of 5 next-gen SERDs commercially viable

Opportunities

→$5–7B WW ER+/HER2- mBC market; 2/3L segment open after elacestrant's slow ramp
→M&A optionality: AZN, Lilly, AbbVie, Pfizer all hold breast-cancer franchises looking to backfill
→OP-3136 is first-in-class KAT6: option value extends beyond breast cancer (prostate now, hematology potential)
→OPERA-02 1L positioning with ribociclib gives separate shot on goal at the largest segment

Threats

!AZN camizestrant (approved 2026) gets first-mover commercial advantage in 2/3L
!Lilly imlunestrant labeled in ESR1-mut subgroup — narrows palazestrant differentiation
!PoS execution risk on Phase 3: even with strong biology, statistical hurdles in 2/3L mBC are real
!Biotech XBI sentiment can reset valuations sector-wide irrespective of company-specific newsflow

article

Summary by assessment area

🟢 Financial risk — Low

$505M cash, zero debt, ~2.4 years runway
Cash covers ~61% of market cap (genuine floor)
Dilution risk acknowledged in FV via FD shares + reserve line

🟡 Execution risk — Moderate/High

OPERA-01 binary readout fall 2026 (class PoS 30–40%)
No commercial infrastructure; partnering likely
Direct competition from AZN camizestrant + Lilly imlunestrant

🔵 Risk/reward — Favorable (asymmetric)

Downside to floor ~47%; base upside +79%; bull +250%
Ratio upside/downside ~3.0x (gate passed)
Dated catalyst within 3–6 months; thesis verifiable

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "OLMA è una biotech binaria con cash che copre ~60% della market cap e un catalizzatore Phase 3 datato (OPERA-01 autunno 2026). Asimmetria reale ma classe-SERD ha PoS storica solo 30-40%.", "en": "OLMA is a binary biotech with cash covering ~60% of market cap and a dated Phase 3 catalyst (OPERA-01 fall 2026). Real asymmetry but next-gen SERD class has historical PoS of only 30-40%."}, "bull_points": [ {"it": "Cash di $505M anchora il downside a ~47%; FV base $17 vs prezzo $9.50 = +79%", "en": "$505M cash anchors downside at ~47%; base FV $17 vs $9.50 price = +79%"}, {"it": "OPERA-01 fall 2026 è un catalizzatore concreto e datato; bull case $30+ se hit", "en": "OPERA-01 fall 2026 is a concrete dated catalyst; bull case $30+ if hit"}, {"it": "Validazione Novartis (OPERA-02 + $250M PIPE) e Bayer (OP-3136 mCRPC)", "en": "Novartis validation (OPERA-02 + $250M PIPE) and Bayer (OP-3136 mCRPC)"} ], "bear_points": [ {"it": "Classe SERD next-gen ha track record misto: 2 di 5 successi (Sanofi/G1 falliti)", "en": "Next-gen SERD class has mixed track record: 2 of 5 succeeded (Sanofi/G1 failed)"}, {"it": "Diluzione +45% YoY e ulteriore raise probabile post-readout", "en": "+45% YoY dilution and additional raise likely post-readout"}, {"it": "Concentrazione single-asset: OPERA-01 determina 80%+ del valore", "en": "Single-asset concentration: OPERA-01 drives 80%+ of value"} ], "risks": [ {"it": "Binary OPERA-01: miss porta il titolo a $4-5 (-50% dal prezzo attuale)", "en": "Binary OPERA-01: a miss takes the stock to $4-5 (-50% from current)"}, {"it": "Competizione AZN camizestrant (approvato) e Lilly imlunestrant restringe spazio commerciale", "en": "AZN camizestrant (approved) and Lilly imlunestrant competition narrows commercial space"}, {"it": "Sell-side mean PT $42 implica PoS 50-60% — più aggressivo del nostro 30%", "en": "Sell-side mean PT of $42 implies 50-60% PoS — more aggressive than our 30%"} ] }

Sources & Disclaimer

Sources: Olema Q1 2026 10-Q, FY2025 10-K, press releases (palazestrant OPERA-01/OPERA-02, OP-3136 ASCO 2026, Bayer & Novartis CTSAs); StockAnalysis.com, MarketBeat, Yahoo Finance (price history); SeekingAlpha, Stock Titan, GlobeNewswire (newsflow); analyst targets: Citi ($62), JPMorgan ($58), Jefferies ($40), Guggenheim ($35), Goldman Sachs ($27), Wolfe Research (Peer Perform). Market data — last verified close 2026-06-22: OLMA $9.51, market cap ~$830M (common only) / ~$960M FD, 52W range $3.89–$36.26, 87.3M common + 13.6M pre-funded warrants outstanding. Short interest: ~9–11% (estimate, sector-typical for binary biotech). Cash & equivalents Q1'26: $505.3M; no debt. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.